Wednesday, May 22

7:00-8:00  Breakfast and Registration
8:00-8:15  Introduction and Welcome from the AES and ILAE

SESSION I: EPILEPSY RESEARCH ROUNDTABLE UPDATE (2017/2018 Meetings)

Moderator: Jacqueline French, MD
8:15-8:35  Infant epilepsy trials: Where are we now?  
          Dennis Dlugos, MD
8:35-8:55  Grouping vs splitting: Should we include more than one syndrome/more than one seizure type in our clinical trials?  
          Nathan Fountain, MD
8:55-9:15  Beyond seizures: How do we assess impact of treatments on the full spectrum of the disease?  
          Michael Sperling, MD
9:15-9:35  Combining multiple outcomes (looking at multiple outcomes of disease in an integrated way)  
          TBD
9:35-9:55  Discussion
9:55-10:20 Break

SESSION II: REGULATORY ISSUES

Moderator: Kimford Meador, MD (to be confirmed)
10:20-10:40  Monotherapy – Integrated approach in US and Europe  
              Jacqueline French, MD
10:40-11:00  EMA Update  
              Michel Baulac, MD
11:00-11:20  NIH Funding Update for Treatment and Device Research and Development  
              John Kehne, PhD
SESSION III: ORPHAN INDICATIONS AND CLINICAL TRIAL ISSUES

Moderator:

11:40-12:00 What have we learned from recent orphan approvals?
Rima Nabbout, MD

12:00-12:20 Trials for ultra-orphans—Are they possible?
Erika Augustine, MD

12:20-1:30 Lunch

1:30-1:40 Clinical trials from “then” to “now”: Through the looking glass-
Lloyd Knapp, PharmD

1:40-2:00 Reconsideration of trial methodology for adjunctive RCT’s—Are we ready for a change?
Emilio Perucca, MD, PhD

2:00-2:20 EEG as a primary end point for trials
Jeffrey Buchhalter, MD, PhD

2:20-2:40 Electronic seizure diaries: Do they help or hurt seizure counting in trials?
Gail Farfel, PhD

2:40-3:10 Panel: I used an electronic seizure diary and this is how it went-
Gail Farfel, PhD, Kimberly Parkerson, MD, PhD, Kevan VanLandingham, MD, PhD

3:10-3:30 Discussion

3:30-3:50 Break

SESSION IV: DEVICE SESSION

Moderator: Dan Friedman, MD

3:50-4:10 EF “My Seizure Gauge”—Update, and how can it change drug development? –
Greg Worrell, MD, PhD

4:10-4:30 Enhancing the seizure counting signal in clinical trials—Wearables? Ambulatory EEG? Other technology? –
Dan Friedman, MD

4:30-4:50 FDA device update
Carlos Pena, PhD, MS

4:50-5:15 Discussion
Thursday, May 23

SESSION V: GENETICS AND DRUG DEVELOPMENT

Moderator:

8:15-8:35 Genetic models for drug development: How predictive are they part I: Stem cells and organoids
John Huguenard, PhD

8:35-8:55 Genetic models for drug development: How predictive are they part 2: Rodent models
Jennifer A. Kearney, PhD

8:55-9:15 Debate: Specificity and sensitivity of genetic models
Dr. Huguenard, Dr. Kearney and Dr. Jack Parent

SESSION VI: PRECLINICAL

Moderator: Karen Wilcox, PhD

9:15-9:35 The new NINDS screening program: Is it getting us to better therapies?
Karen Wilcox, PhD

9:35-9:55 Everything old is new again: Do the “standard” screening tests (MES, PTZ) have any place in modern drug screening?
Steve White, PhD

9:55-10:15 Discussion

10:15-10:45 Break

SESSION VII: ANTIEPILEPTOGENESIS AND DISEASE MODIFICATION

Moderator: Marc Dichter, MD, PhD

10:45-11:05 NINDS antiepileptogenesis workshop: take home messages
Roy Twyman, MD

11:05-11:25 Repurposing drugs for antiepileptogenesis: A combinatorial approach
Wolfgang Löscher, DVM, PhD

11:25 -11:45 Antiepileptogenesis trial post TBI: Ready for prime time?
Paul Vespa, MD

11:45-12:05 Contribution of inflammation to perpetuation of the seizure focus
Annamaria Vezzani, PhD
12:05-12:30  Discussion
12:30-2:15  Lunch (Not included in registration)

2:15-5:30  SHARK TANK COMPETITION
2:00-2:15  Update from 2018 Winner
Panelists  TBD
Finalists

5:30  RECEPTION

2018 Epilepsy Foundation Lifetime Accelerator Award
Recipient:

Friday, May 24  PIPELINE

SESSION VIII: DEVICE PIPELINE AND PLATFORMS

SESSION IX: DRUG PIPELINE

PRE-CLINICAL
Moderator:  Marc Dichter, MD, PhD

CLINICAL
Moderator:  Bernd Schmidt, MD, PhD